Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
130 hedge funds and large institutions have $732M invested in Revance Therapeutics, Inc. in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 21 closing their positions.
91% more call options, than puts
Call options by funds: $1.66M | Put options by funds: $869K
37% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 38
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 21
3% less funds holding
Funds holding: 134 → 130 (-4)
12% less capital invested
Capital invested by funds: $828M → $732M (-$96.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$35.2M |
| 2 |
Goldman Sachs
New York
|
+$12.9M |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$10.9M |
| 4 |
BlackRock
New York
|
+$6.59M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$5.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$21.7M |
| 2 |
NCM
NovaQuest Capital Management
Raleigh,
North Carolina
|
-$19.8M |
| 3 |
PC
Polar Capital
London,
United Kingdom
|
-$15M |
| 4 |
DM
Deerfield Management
New York
|
-$14.6M |
| 5 |
BAMCO Inc
New York
|
-$6.64M |
RVNC Hedge Fund Activity: Q1 2020 in Review
130 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q1 2020, worth a combined $732M — down 12% from $828M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of RVNC and 19 opened new positions — a net loss of 2 holders — while 38 trimmed existing stakes and 52 added.
The largest buyer was Jennison Associates, opening a new position worth an estimated $35.2M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $21.7M.
- 130 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q1 2020, down from 134 in Q4 2019.
- Funds reported $732M of Revance Therapeutics, Inc. stock for Q1 2020, down 12% quarter-over-quarter.
- 19 funds opened new Revance Therapeutics, Inc. positions in Q1 2020 and 21 closed out, a net change of -2 holders.
- The largest Revance Therapeutics, Inc. buyer in Q1 2020 was Jennison Associates, an estimated $35.2M added.
- The largest Revance Therapeutics, Inc. seller in Q1 2020 was ArrowMark Colorado Holdings, an estimated $21.7M sold.
Based on aggregated 13F filings for Q1 2020.